Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49: Pembrolizumab Plus Chemotherapy in HR+/HER2- Advanced Breast Cancer
NCT04895358Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
A Phase 3 trial of pembrolizumab in breast cancer, sponsored by Merck & Co.. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04895358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895358.